September 18, 2025Frontiers in ImmunologyOpen Access

Clinicopathological characteristics and treatment patterns of combined small-cell lung cancer: a real-world single-center study with a mini review

View Full Paper

Ask AI

Bookmark

Patients with combined small-cell lung cancer showed a disease control rate of 85.19%.
The tumor response rate was 51.85% in those treated, with median progression-free survival at 9.70 months.
The study included 30 patients, predominantly males, with diverse treatment options like immunochemotherapy and chemotherapy.
Findings highlight potential benefits of immunotherapy over chemotherapy in managing combined small-cell lung cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Single-center study evaluated treatment outcomes in combined small-cell lung cancer patients, suggesting immunotherapy may be beneficial.

Gong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark